Core Viewpoint - Shouxiangu (603896.SH) has not yet engaged in external investments related to short videos and short dramas, focusing instead on brand promotion and product sales through new media platforms like Douyin, WeChat Video Accounts, and Xiaohongshu [1] Group 1 - The company is currently leveraging new media platforms for brand promotion and product sales [1] - Future strategies will involve a careful assessment of the collaborative value of various new media formats in brand building and market education [1] - The company aims to promote the innovative dissemination of traditional Chinese medicine culture [1]

Core Viewpoint - Shouxiangu has developed a proprietary wall-breaking technology for Ganoderma lucidum spore powder, which has received multiple international patents and is recognized as an internationally leading technology [2] Group 1: Technology and Intellectual Property - The wall-breaking technology for Ganoderma lucidum spore powder is a unique core technology of the company [2] - The technology has been granted national invention patents as well as patents in Japan, the United States, Europe, South Korea, and South Africa, establishing a comprehensive independent intellectual property protection system [2] Group 2: Health Benefits and Efficacy - Research results indicate that the triterpenes in the wall-broken Ganoderma lucidum spore powder can directly inhibit the growth and metastasis of tumor cells [2] - Ganoderma polysaccharides can regulate the immune system, enhance the body's defense capabilities, alleviate excessive inflammatory responses, and balance immune checkpoints [2] - The product helps reduce common adverse reactions caused by tumor surgeries, chemotherapy, and targeted therapies, such as fatigue, bone marrow suppression, emotional distress, and sleep disorders, thereby improving patients' quality of life and creating a synergistic effect with conventional anti-tumor treatments [2]

Group 1 - The company Shouxiangu (603896) is currently working on the expansion of its pre-processing workshop, which is necessary for the production of Er Dong Tang [1] - The completion of the pre-processing workshop expansion requires the successful verification of three batches of products and passing a compliance inspection organized by the drug regulatory authority [1]

Group 1 - The company is currently advancing the pre-treatment workshop expansion work necessary for the production of Er Dong Tang [2] - The completion of the pre-treatment workshop expansion requires the successful verification of three batches of products and passing the compliance inspection organized by the drug regulatory authority [2]

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step in the internationalization and standardization of traditional Chinese medicine (TCM), providing a unified framework for the global industry [5][7]. Group 1: Standard Release and Significance - The ISO international standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially released during a seminar focused on the high-quality international development of TCM [5]. - This standard establishes a comprehensive standardization system for the global broken wall Ganoderma spore powder industry, covering aspects from raw materials to production processes and quality control [7]. - The standard sets a minimum requirement of ≥95% wall-breaking rate and introduces a multi-index evaluation system for active components, ensuring both traditional practices and modern technology are integrated [7]. Group 2: Impact on Consumers and Industry - For consumers, the standard provides a more reliable product guarantee, enabling better assessment of product safety and effectiveness, and helping to distinguish genuine products from counterfeits [7]. - The company, Shouxiangu, has been a key player in TCM standardization, having led or participated in the formulation of over 100 TCM standards, including 8 international standards [7][8]. Group 3: Future Directions and Challenges - The standardization initiative is expected to drive the internationalization of TCM, with a focus on quality and safety, while also addressing the unique challenges posed by the traditional practices of TCM [9][10]. - Experts emphasize the need for a balance between standardization and the unique characteristics of TCM, advocating for a system that integrates traditional wisdom with modern scientific approaches [10][11]. - The seminar highlighted the importance of protecting authentic medicinal materials and educating international markets as key factors in promoting the internationalization of TCM [11].

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step towards the internationalization of traditional Chinese medicine (TCM), providing a unified framework for quality and safety in the global market [4][6]. Group 1: Standard Release and Significance - The ISO standard (ISO/TS 25006:2025) for Broken Wall Ganoderma Spore Powder was officially released, establishing a comprehensive standardization system from raw materials to production and testing [4][5]. - This standard serves as a "world language" for TCM, facilitating the internationalization of Zhejiang-produced traditional medicine [4][6]. Group 2: Production and Quality Control - The standard specifies raw material sourcing requirements and sets a critical parameter of ≥95% wall-breaking rate, ensuring standardized production control [5]. - It introduces a fingerprinting multi-index evaluation system for active components, balancing traditional practices with modern technology [6]. Group 3: Consumer Impact and Industry Leadership - For consumers, the standard enhances product reliability, enabling better assessment of safety and efficacy, and helping to distinguish quality products [6]. - The company, Shouxiangu, has led the development of over 100 TCM standards, including 8 international standards, contributing to the global recognition of TCM [6][7]. Group 4: Challenges and Innovations in TCM - The implementation of the standard addresses a global quality gap in TCM and injects new momentum into the internationalization of the industry [7]. - Experts emphasize the need for a balance between traditional TCM practices and modern standardization requirements, highlighting the challenges posed by differing legal and cultural contexts [7][8]. Group 5: Future Directions - The company aims to continue its efforts in international standard formulation, promoting more Zhejiang-produced medicinal materials globally and enhancing cooperation with countries along the "Belt and Road" initiative [6][8]. - The conference signifies a new phase in TCM internationalization, focusing on standard leadership, industry collaboration, and global sharing [8].

Core Viewpoint - The establishment of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the internationalization of traditional Chinese medicine (TCM) and sets a quality benchmark for the global market [1][2]. Group 1: Standardization and Internationalization - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially implemented, facilitating the entry of Zhejiang-produced traditional Chinese medicine into international markets [1]. - The standard fills a global quality regulation gap in the field of Ganoderma spore powder, providing a unified measurement system for the industry [1][3]. - The standard includes specifications for raw material sources, a minimum breaking rate of 95%, and a multi-index quality control system for active components [1][2]. Group 2: Industry Growth and Economic Impact - Following the implementation of previous ISO standards for Ganoderma and Dendrobium, international trade volumes for these products increased by 284.5% and 37.5% respectively [3]. - The Zhejiang province's TCM industry is projected to achieve significant growth, with industrial output, new product output, and export scale expected to reach 5 times, 6.3 times, and 2.7 times the levels of 2005 by 2024 [3]. Group 3: Research and Development - The company has established a robust research platform, collaborating with various international institutions to enhance product technology and gather internationally recognized scientific data [2][3]. - The company has led the development of over 100 TCM standards, including 8 international standards, with several recognized by countries like the UK and Germany [2]. Group 4: Future Directions - Experts suggest that the next step for TCM is to develop a comprehensive standard system covering the entire industry chain, including cultivation, processing, quality inspection, and clinical evaluation [4]. - The company aims to continue its efforts in international standard formulation and promote more local medicinal materials globally, enhancing cooperation with countries along the Belt and Road Initiative [4].

Core Viewpoint - The release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the standardization of traditional Chinese medicine (TCM), promoting quality and international development in the industry [1][2][4]. Group 1: Standardization and Innovation - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" will be implemented in July 2025, following previous standards for other TCM products [2]. - The standard establishes key parameters such as raw material sources, a minimum 95% breaking rate, and a multi-index quality control system, enhancing production technology standardization [4]. - Experts emphasize that TCM standardization is a process of deriving scientific rules from clinical practices to form internationally recognized standards [4]. Group 2: Economic Impact - The implementation of ISO standards has led to significant increases in international trade, with related products seeing trade growth of 284.5% and 37.5% for Ganoderma and Dendrobium, respectively [5]. - The standards have been adopted in 31 countries, including major markets like the US, Canada, Australia, and Germany, facilitating trade recognition [5]. Group 3: International Collaboration - Collaborations with international institutions, such as clinical research on TCM's anti-tumor effects and cardiovascular benefits, are enhancing the scientific basis for standardization [6]. - The Zhejiang provincial government plans to strengthen the internationalization of TCM standards, focusing on local medicinal materials and specialty TCM products [6]. Group 4: Future Directions - The establishment of a comprehensive standard system covering the entire industry chain, from cultivation to clinical evaluation, is seen as essential for enhancing the industry's competitiveness [7]. - The company aims to deepen international standard formulation and promote local medicinal materials globally, particularly in countries along the Belt and Road Initiative [9].

Group 1 - Since January 2026, the A-share market has seen a wave of shareholder return activities, with 8 listed companies announcing various ways to reward investors, including physical gifts, discount coupons, and service rights [1][2] - This trend reflects the maturation of the Chinese capital market, indicating a diversification in how listed companies reward investors and a shift towards emotional connection and long-term value recognition in investor relations management [1][3] - Companies like Chen Ke Ming Food Co., Ltd. and Zhejiang Shou Xian Gu Pharmaceutical Co., Ltd. have initiated shareholder return activities, offering free products to shareholders based on their holdings [1][2] Group 2 - Other companies such as Quanjude Group, Furui Group, and Panda Dairy have also launched shareholder return activities in January, expressing gratitude to shareholders through various means [2] - The strategy of using products or services to reward shareholders enhances their perception of the company's value and fosters trust and long-term investment willingness, while also serving as a platform for brand promotion [2][3] - Over the past decade, more than 70 listed companies in the A-share market have conducted shareholder return activities, with over 30 companies doing so in 2025 across various sectors including consumer, cultural tourism, medical, and technology [2]